These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17875726)

  • 1. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
    Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
    Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
    Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
    Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
    Piersma SJ; Jordanova ES; van Poelgeest MI; Kwappenberg KM; van der Hulst JM; Drijfhout JW; Melief CJ; Kenter GG; Fleuren GJ; Offringa R; van der Burg SH
    Cancer Res; 2007 Jan; 67(1):354-61. PubMed ID: 17210718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
    Chandy AG; Nurkkala M; Josefsson A; Eriksson K
    Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
    Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
    Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice.
    Gendron KB; Rodriguez A; Sewell DA
    Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):327-32. PubMed ID: 16549754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
    Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
    Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
    Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
    Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
    Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer.
    Jeon YH; Lee HW; Lee YL; Kim JE; Hwang MH; Jeong SY; Lee SW; Ahn BC; Ha JH; Lee J
    Cancer Biother Radiopharm; 2011 Dec; 26(6):671-9. PubMed ID: 22091632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.